Patterns of presentation and diagnosis of patients with Wegener's granulomatosis: ENT aspects by Srouji, IA et al.
The Journal of Laryngology &amp; Otology
http://journals.cambridge.org/JLO
Additional services for The Journal of Laryngology &amp; Otology:
Email alerts: Click here
Subscriptions: Click here
Commercial reprints: Click here
Terms of use : Click here
Patterns of presentation and diagnosis of patients with Wegener's 
granulomatosis: ENT aspects
I A Srouji, P Andrews, C Edwards and V J Lund
The Journal of Laryngology & Otology / Volume 121 / Issue 07 / July 2007, pp 653 ­ 658
DOI: 10.1017/S0022215106005032, Published online: 04 December 2006
Link to this article: http://journals.cambridge.org/abstract_S0022215106005032
How to cite this article:
I A Srouji, P Andrews, C Edwards and V J Lund (2007). Patterns of presentation and diagnosis of patients with Wegener's 
granulomatosis: ENT aspects. The Journal of Laryngology & Otology, 121, pp 653­658 doi:10.1017/S0022215106005032
Request Permissions : Click here
Downloaded from http://journals.cambridge.org/JLO, IP address: 144.82.107.85 on 23 Oct 2012
Main Article
Patterns of presentation and diagnosis of patients with
Wegener’s granulomatosis: ENT aspects
I A SROUJI, P ANDREWS*, C EDWARDS†, V J LUND‡
Abstract
Design: a cross-sectional study.
Participants: One hundred and ninety-nine patients with Wegener’s granulomatosis belonging to a
patient self-help group.
Main outcome measures: Mode of initial presentation; diagnosis timescales and delay; rhinologic
involvement; and treatment.
Results: Sixty-three per cent of patients initially presented with ENT-related symptoms. Ninety-two per
cent faced a delay in their diagnosis of more than one month, a pattern which has not improved over the
last few decades and which compares unfavourably with North American figures. Rhinologic and otologic
symptoms are a common occurrence in up to 85 and 50 per cent of Wegener’s granulomatosis patients,
respectively, attracting varying degrees of targeted treatment.
Conclusions: As sinonasal and other ENT symptoms are so common at the presentation of Wegener’s
granulomatosis, it is clear that the otolaryngologist has an important role in its diagnosis and treatment.
There are long delays in the diagnosis and possible under-treatment of the ENT symptoms of this
condition, highlighting the need for greater awareness, particularly in the ENT community.
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Introduction
Wegener’s granulomatosis is a rare, multisystem
disease with numerous otorhinolaryngological mani-
festations. More than 80 per cent of patients with
this diagnosis experience rhinological morbidity,
and 20–40 per cent experience otological morbidity
at some point during their life.1 Furthermore, an
increasing number of patients with upper airway
disease such as subglottic stenosis are eventually
found to have limited forms of Wegener’s granulo-
matosis.2 Many Wegener’s granulomatosis patients
will initially present to the physician or otolary-
ngologist with ENT-related symptoms. Due to the
relative rarity of this disease and its presentation in
the midst of common ENT pathology, Wegener’s
granulomatosis patients encounter not only a poss-
ible delay in their diagnosis but also variable
amounts of therapy directed at their ENT-related
morbidities.
One large survey from the United States3 assessed
some of these aspects in general. However, no pre-
vious study has investigated such a large group of
British Wegener’s granulomatosis patients, with a
focus on ENT practice.
This study aimed to explore the patterns of presen-
tation and diagnosis of patients with Wegener’s gran-
ulomatosis. Furthermore, it investigated their ENT
symptomatology and the ways in which they were
treated.
Methods
Ethical approval for the study was obtained from the
Royal Free Hospital and Medical School research
ethics committee.
A postal questionnaire was sent to all members of
the Wegener’s granulomatosis patients’ own UK self-
help group, the Stuart Strange Vasculitis Trust. This
questionnaire sought basic information from each
patient, including the timescale of their diagnosis,
their symptoms and their treatment details. The
questionnaire had been previously validated with a
group of clinically confirmed Wegener’s granuloma-
tosis patients, using methodology by Juniper and
Guyatt.4 We excluded from the study those question-
naires in which the patient’s age, sex or Wegener’s
granulomatosis diagnosis were not confirmed.
Patients’ demographic details were derived from all
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valid responses. The times of symptom onset, presen-
tation to a physician or ENT surgeon, and actual
diagnosis of Wegener’s granulomatosis were
recorded. Delay in diagnosis was calculated from the
time of presentation to a specialist.
The questionnaire enquired about any previous or
current history of sinonasal morbidity, including a
selection of relevant nasal and aural symptoms, and
any history of previous nasal surgery. Treatment
regimen profiles, including systemic immunosuppres-
sants and any topical nasal treatment, were recorded
for each patient.
Results
Population, presentation and diagnosis
Of all the questionnaires sent to members of the
Stuart Strange Vasculitis Trust, 781 were to Wegener’s
granulomatosis patients. The seven responses
received from patients’ relatives, and responses
missing essential information, were excluded from
the study. Valid responses were received from 199
patients with Wegener’s granulomatosis (25.5 per
cent), and the remainder of the analysis is concerned
with these patients. Sixty-five per cent of these
respondents were women and 35 per cent were
men. Ninety-three per cent of respondents described
themselves as white Caucasian. The mean age of
Wegener’s granulomatosis patients was 58.2 years
(median 59, range 17–81 years).
The average time since diagnosis was eight years
(range, 1 month to 23 years and 3 months). The
average age at diagnosis was 50 years (range 13–78
years). Figure 1 shows the age distribution of the
study group at the time of the survey and respon-
dents’ ages at diagnosis.
Sixty-three per cent of the Wegener’s granuloma-
tosis patients initially presented with an ENT-related
symptom: 41 per cent of all presenting symptoms
were rhinological; 16 per cent were otological; and
6 per cent related to the pharynx, larynx or trachea.
Figure 2 shows respondents’ presenting symptoms,
by bodily system.
The nose and paranasal sinuses were the common-
est presenting systems in all age groups. These were
the site of presenting symptoms in 50 per cent of
patients diagnosed before the age of 60 years, com-
pared with only 27 per cent of those diagnosed
when older than 60 years (p ¼ 0.016 for those each
side of 60 years of age at diagnosis (difference in pro-
portions test, Statistica version 6.1 software, Statsoft
Inc, Tulsa, Oklahoma, USA)). The younger age
groups also had a general predilection to other
head and neck related modes of presentation
(Figure 3). In comparison, patients diagnosed at a
later age (over 60 years) were more likely to initially
present with renal, pulmonary and other manifes-
tations than younger patients (p , 0.001, difference
in proportions test).
Diagnosis timescale data (i.e. time of initial
presentation to a physician and actual time of diagno-
sis with Wegener’s granulomatosis) was available for
183 patients (92 per cent). Ninety-two per cent of
patients reported that their actual diagnosis with
Wegener’s granulomatosis was delayed by over one
month (49 per cent by one to six months, 20 per
cent by 6–12 months and 23 per cent by more than
12 months). The overall average delay in diagnosis
was as long as seven months.
The average delay in diagnosis was greater for
patients presenting with symptoms in the head and
neck systems combined (i.e. sinonasal, ear, eye and
upper respiratory tract) than in those presenting
with non-head and neck systems combined
(i.e. lower respiratory tract, renal, nervous system,
musculoskeletal, cutaneous and any other presen-
tation). The mean delay was 9.0 months in the
FIG. 1
Respondents’ ages at diagnosis and at survey (to nearest whole
number).
FIG. 2
Respondents’ (n ¼ 199) initial presenting system. URT ¼
upper respiratory tract; LRT ¼ lower respiratory tract; CNS ¼
central nervous system; PNS ¼ peripheral nervous system
FIG. 3
Presenting system in respondents diagnosed at ,40 years
(n ¼ 191), 40–60 years and .60 years of age. URT ¼ upper
respiratory tract (including pharynx, larynx and trachea);
LRT ¼ lower respiratory tract; MSK ¼ musculoskeletal
system
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combined head and neck systems presentation group
(standard deviation (SD) 11.0), compared with 5.9
months in the combined non-head and neck
systems presentation group (SD 6.1) (p ¼ 0.054;
t-test, independent groups) but this was not statisti-
cally significant due to the high variability of delay
in diagnosis within each system). Figure 4 shows the
delay in diagnosis by presenting bodily system. Fur-
thermore, the extent of delay in diagnosis did not
seem to improve over the years, as demonstrated by
Figure 5. Only a minor negative correlation (20.11)
existed between the length of delay and year of diag-
nosis, indicating little improvement over time.
ENT symptomatology and treatment
Twenty per cent (37/183) of the Wegener’s granulo-
matosis patients had never received an ENT consul-
tation. Twenty-three per cent (43/183) had been
diagnosed with Wegener’s granulomatosis prior to
their first ENT consultation. The remaining 56 per
cent (103/183) of patients had been seen by otolar-
yngologists prior to diagnosis with Wegener’s granu-
lomatosis. Over 50 per cent of Wegener’s
granulomatosis patients reported aural fullness and
42 per cent reported dizziness to different degrees.
Twenty-nine per cent of the study group also
reported otalgia at the time of the survey. Eighty-five
per cent of patients reported a history of sinonasal
morbidity at some stage during the course of their
illness, with 64 per cent reporting active sinonasal
involvement at the time of the survey. However,
when asked about specific sinonasal symptoms, the
patients reported even higher levels of current sino-
nasal morbidity, as shown by Figure 6. The most pro-
minent symptoms included nasal crusting (affecting
75 per cent of patients), excessive nose-blowing
(70 per cent), nasal obstruction (65 per cent) and
epistaxis (59 per cent). Twenty-five per cent of
patients were unhappy with the shape of their nose.
Treatment profile data were available for 198/199
patients. Eighty-two per cent (163/198) of patients
were receiving systemic immunosuppressant medi-
cation to varying degrees, and 53 per cent (105/
198) were taking more than one agent. Topical
nasal treatment was prescribed to 27 per cent
(54/198) of patients, including steroid sprays (22/
198; 11.1 per cent), antibiotic creams (19/198; 9.6
per cent) and nasal douches (in as few as 13.1 per
cent of patients). Nine patients (4.5 per cent)
were receiving both topical steroid spray and
nasal douches. Three (1.5 per cent) patients were
receiving both a topical cream and a douche. No
patient reported receiving all three topical treat-
ments. A breakdown of all treatments is shown in
Figure 7.
Discussion
Wegener’s granulomatosis was named after
Frederick Wegener in 1936,5 but it had probably
been described earlier by Heinz Klinger in 19316
at the University of Berlin. Up to 1967, 138 unequi-
vocal cases of Wegener’s granulomatosis had been
reported in the literature.7 This was at a time
when the condition was considered almost invari-
ably fatal within two years, and prior to the
advent of immunosuppressant therapy. The con-
dition’s aetiology remains obscure, as does its inci-
dence, particularly since the recognition of limited
forms of the condition. In some individuals, it
may present and remain confined to a particular
FIG. 4
Respondents’ average delay in diagnosis, by presenting system.
Dark shading indicates presentation with systems in the head
and neck region. URT ¼ upper respiratory tract; LRT ¼ lower
respiratory tract; CNS ¼ central nervous system; PNS ¼
peripheral nervous system; MSK ¼ musculoskeletal system
FIG. 5
Respondents’ delay in diagnosis, by year of diagnosis, showing
no trend in diagnosis delay over the last few decades. (n ¼ 183,
correlation coefficient ¼ 20.11).
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system for many years, often adding difficulty to an
already challenging diagnostic process. It is
unknown what proportion of these patients ulti-
mately progress to classical, multisystem disease.
The ability to diagnose the condition has been
significantly improved by the advent of the
Antineutrophil cytoplasmic antibodies assay in
1987,8 which has a high specificity (80 per cent)
and sensitivity (90 per cent) in multisystem
disease. However, the latter may drop to 50–60
per cent in localised forms of the condition.
The average time from diagnosis with Wegener’s
granulomatosis to questionnaire receipt was quite
long – eight years in the studied group (although it
ranged widely, from one month to over 23 years).
The majority of respondents (53 per cent) were diag-
nosed in their fifth and sixth decades; at the time of
the study, the majority of respondents (52 per cent)
were in their sixth and seventh decades. However,
it should be noted that patients as young as 13
years and as old as 78 years can present with this
condition.6
This study confirms the frequency of sinonasal
symptoms at the presentation of Wegener’s granulo-
matosis; this was notably higher in younger patients.
Of the nasal symptoms, nasal crusting, discharge,
blockage and bleeding were the most prominent,
as anticipated. As we have previously reported,
Wegener’s granulomatosis patients may present
with various otologic symptoms (16 per cent; e.g.
persistent otitis media, sensorineural deafness
and vertigo), upper aerodigestive tract symptoms
(6 per cent; e.g. gingivitis and ulceration, which
may lead to oro-antral fistula), and laryngeal symp-
toms (e.g. hoarseness and dyspnoea, which may be
associated with cranial nerve palsies or isolated
sub-glottic stenosis).
FIG. 6
Respondents’ (n ¼ 199) sinonasal morbidity. Dark bars ¼ nasal symptoms that are specific to Wegener’s granulomatosis.
FIG. 7
Respondents’ current treatment. Dark bars ¼ nasal symptoms
that are specific to Wegener’s granulomatosis.
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The majority of Wegener’s granulomatosis patients
reported receiving systemic immunosuppressants,
suggesting that they had active disease. Prednisolone
was the most popular (71 per cent), followed by
azathioprine (41 per cent), with fewer patients
taking methotrexate, cyclophosphamide or mycophe-
nolate mofetil. This range reflects the broad spectrum
of physicians managing Wegener’s granulomatosis
throughout the United Kingdom. Despite active
nasal symptoms in 63 per cent of respondents, a rela-
tively small number were receiving topical treatment
(see Figure 7). This is an important finding in the
light of theories implicating nasal bacterial carriage
in the exacerbation and relapse of controlled
Wegener’s granulomatosis.9
The reported significant delay in diagnosis is dis-
turbing, given that the majority of the Wegener’s
granulomatosis patients (63 per cent) first presented
with ENT symptoms. Intriguingly, the delay was
greater for those with head and neck system involve-
ment at initial presentation. It is also very noteworthy
that 56 per cent of these individuals had been seen by
ENT surgeons prior to diagnosis, some of whom by
inference had failed to recognise the condition.
Furthermore, awareness of Wegener’s granulomato-
sis in the UK has not increased over the last three
decades, as evidenced by consistent periods of
delay, including delays of more than 6–12 months
for one-fifth of respondents and delays of more
than 12 months in another 23 per cent. This is
despite improvements in diagnostic tests.
The tendency towards head and neck involvement
in younger patients and non-ENT involvement in
older patients is in agreement with previously pub-
lished findings.10 Interestingly, our community-based
study showed an even higher prevalence of nasal
blockage, crusting, bleeding and hyposmia than that
found in a previously published, clinically selected
rhinology-immunology study group.11
Figure 8 compares our findings for delay in diagno-
sis with those of a previously published North
American study.3 It can be seen that a significantly
larger proportion of UK than US Wegener’s granulo-
matosis patients faced a diagnosis delay of more than
one month (92 per cent compared with 79 per cent,
respectively; p , 0.001, difference of proportions
test) as well as delays of other durations.
. ENT involvement is common in Wegener’s
granulomatosis, but most existing figures are
from tertiary care units, with their associated
specialty-related bias
. This community-based study confirms not only
the high prevalence of ENT involvement but
also its frequency at the initial presentation of
Wegener’s granulomatosis, highlighting the
important role of otolaryngologists in the
diagnosis of this condition
. There were significant delays in the diagnosis
of Wegener’s granulomatosis patients,
particularly when presenting with symptoms in
the head and neck region, demonstrating the
need for greater awareness of the condition
within the ENT community
. Wegener’s granulomatosis patients showed a
sinonasal symptom pattern, with
under-treatment of significant, Wegener’s
granulomatosis-related nasal symptoms
In the literature, the reported incidence of system
involvement in Wegener’s granulomatosis is influ-
enced by the speciality of the reporting unit. The
present study was conducted on a relatively large
cohort of patients who had been diagnosed and
were being treated for Wegener’s granulomatosis.
Sourcing these patients via a self-help organisation
avoided any selection bias, as their diagnosis and
care were being undertaken by a wide range of
FIG. 8
Comparison of delay in diagnosis, between patients in the present study (UK) and those in the study by Abdou et al. 2002 (North
America).3
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clinicians. However, the study was liable to detec-
tion bias in that it relied on the patients’ confir-
mation of their diagnosis, history and treatment,
without the possibility of clinical verification. None-
theless, for a disease of such potential seriousness,
in patients motivated enough to belong to a self-
help organisation, this information is likely to be
as accurate, if not more so, than a retrospective
assessment of medical notes, with all its intrinsic
limitations.
The survey response rate of just over 26 per cent
seems modest but should be considered as a
minimum; as some of the excluded survey question-
naires were returned by patient’s relatives, it is
unknown how many unreturned questionnaires
were not actually received by Wegener’s granuloma-
tosis patients. For this reason, the true return rate is
likely to be significantly higher than the above
figure. In addition, when considering such a rare con-
dition as Wegener’s granulomatosis (UK incidence
of 10.2/million/year and prevalence of 25/100
000),12 our sample size of 199 Wegener’s granuloma-
tosis patients would, by extrapolation, be comparable
to a sample group of 30 000 patients in a study of
nasal polyps (prevalence of 4.2 per cent of adult
population).13
Conclusion
This study clearly demonstrates the need for greater
awareness of Wegener’s granulomatosis, particularly
in the ENT community. It also highlights the fact that
particular symptoms (such as nasal crusting and
bleeding, and indeed a range of other ENT symp-
toms which do not respond to conventional treat-
ment) should raise the possibility of this diagnosis.
A diagnosis of Wegener’s granulomatosis should be
especially considered in patients who report levels
of malaise which are disproportionate to their ENT
symptoms and clinical findings.
We also hope that this study will raise otolaryn-
gologists’ awareness of the Stuart Strange Trust,
the UK’s patient help group for Wegener’s granulo-
matosis patients as well as for those suffering from
any of the associated vasculitides (e.g. Churg–
Strauss syndrome and microscopic polyangiitis).
The trust was established in 1992 by family and
friends in memory of Stuart Strange, a Wegener’s
granulomatosis patient who had started raising
money for research into Wegener’s granulomatosis
but who tragically succumbed to his disease. The
trust publishes a newsletter at least twice a year
and provides support to patients and their families.
Referring patients to such self-help groups can
help ease the tremendous isolation many feel when
diagnosed with a rare condition such as Wegener’s
granulomatosis.
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